Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07197307 | Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)(CLEAR) | recruiting | Phase 2 | 120 | Universität MünsterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | recruiting | Phase 1 | 180 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 92 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07652281 | A Clinical Study of SHR-5421 in Patients With Multiple Myeloma | recruiting | Phase 1 | 97 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05365659 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | recruiting | Phase 1 | 140 | Iksuda Therapeutics Ltd.INDUSTRY | 5 | Jul 29, 2026 | clinicaltrials |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | recruiting | Phase 2 | 58 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06319456 | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | recruiting | Phase 3 | 344 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant | recruiting | Phase 1 | 46 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07099391 | A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07272499 | Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease | recruiting | Phase 2 | 25 | Ruijin HospitalOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07335887 | Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis | recruiting | Phase 2 | 39 | Peking University People's HospitalOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05135351 | Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy | recruiting | N/A | 30 | University of NebraskaOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07654426 | The CARDIOPROTECT Trial | recruiting | Phase 2 | 60 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07121946 | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma | recruiting | Phase 1 | 42 | LTZ Therapeutics, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07082686 | A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) | recruiting | Phase 2 | 75 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06765317 | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07094048 | Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager(CHUQUL_HO001) | recruiting | Phase 4 | 80 | CHU de Quebec-Universite LavalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07236502 | Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma(MFM) | recruiting | N/A | 184 | Medical College of WisconsinOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07429721 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. | recruiting | Early Phase 1 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07494565 | Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL | recruiting | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07719556 | Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) | recruiting | Phase 2 | 39 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04504526 | Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases | recruiting | Early Phase 1 | 50 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07101705 | An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies | recruiting | Early Phase 1 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07200089 | Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) | recruiting | Phase 1 | 52 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06471738 | Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | recruiting | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06855121 | The Norwegian Immunotherapy in Multiple Myeloma Study(NIMMS) | recruiting | — | 400 | St. Olavs HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06863402 | Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype | recruiting | Phase 2 | 32 | Roswell Park Cancer InstituteOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07205315 | A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia | recruiting | Early Phase 1 | 28 | Grit BiotechnologyINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715630 | In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma | recruiting | Phase 1 | 15 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05052528 | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 36 | University of California, DavisOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06461988 | Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | recruiting | Phase 2 | 20 | Stanford UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07224672 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis(ALANIS) | recruiting | Phase 2 | 60 | GlaxoSmithKlineINDUSTRY | 2 | Jul 17, 2026 | clinicaltrials |
| NCT05469893 | Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | recruiting | Phase 2 | 52 | Irene Ghobrial, MDOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06121843 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | recruiting | Phase 1 | 187 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 2 | Jul 16, 2026 | clinicaltrials |
| NCT06364423 | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 276 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients(STOMP) | recruiting | Phase 1 / Phase 2 | 300 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT07649525 | Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level(iFIT) | recruiting | Phase 3 | 1,226 | University of LeedsOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05371808 | Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: | recruiting | — | 247 | Canadian Cancer Trials GroupNETWORK | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05847569 | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma | recruiting | Phase 2 | 62 | Mayo ClinicOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06340646 | Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) | recruiting | N/A | 990 | Washington University School of MedicineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03308474 | Myeloma Registry Platform (MYRIAM)(MYRIAM) | recruiting | — | 2,200 | iOMEDICO AGINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | recruiting | Phase 2 | 315 | Miltenyi Biomedicine GmbHINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT05650632 | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 210 | AbbVieINDUSTRY | 7 | Jul 13, 2026 | clinicaltrials |
| NCT06043011 | Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms(RUBIN) | recruiting | — | 2,950 | iOMEDICO AGINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06644625 | CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study | recruiting | — | 1,665 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06870760 | Pre-malignant States to Hematologic Malignancies in Firefighters | recruiting | — | 300 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 30, 2026source: clinicaltrials